Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/01/21
End: 12/31/30
Due: 12/31/31
Phase: N/A
Priority: Normal
Start: 07/31/25
End: 03/31/29
Due: 03/31/30
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | NCT05043688 | Zhigang Li | user2@example.com | None | 2021-09-01 | 2030-12-31 | 2031-12-31 | - | - | 2025-07-14 |
| Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC | NCT06861894 | Zhigang Li | user2@example.com | None | 2025-07-31 | 2029-03-31 | 2030-03-31 | - | - | 2025-07-14 |